Moderna Stock News

Related Stocks: MRNA , AMD , LLY , NULV , NEE , NOW , WRBY , GE , EMXC , SPXT , DVY , IAU , PTC , SCI , VEEV , BIL , VRNS , TER ,

Moderna, Inc.''s (NASDAQ: MRNA ) vaccine franchise has further legs to play out, according to an analyst at Morgan Stanley. The Moderna Analyst: Matthew Harrison has an Equal-weight rating and a $313 price target for Moderna shares. The Moderna Thesis: The success of COVID-19 mRNA vaccines has led to the development of additional respiratory vaccines using the technology, Harrison said in a note. Related Link: Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates The next key vaccine readout, the analyst Full story available on Benzinga.com

After a magnificent run, Moderna (MRNA) stock has recently lost some of its luster. Over the past month some notable of events have resulted in the shares shedding

WASHINGTON: Pfizer, BioNTech and Moderna are making combined profits of $65,000 every minute from their highly successful Covid-19 vaccines while the worlds poorest countries remain largely unvaccinated, according to a new analysis. The companies have sold the vast majority of their doses to rich countries, leaving low-income nations in the lurch, said the Peoples Vaccine Alliance (PVA), a coalition campaigning for wider access to Covid vaccines, which based its calculations on the firms own earning reports. The Alliance estimates that the trio will make pre-tax profits of $34 billion this year between them, which works out to over $1,000 a second, $65,000 a minute or $93.5 million a day. It is obscene that just a few companies are making millions of dollars in profit every single hour, while just two percent of people in low-income countries have been fully vaccinated against coronavirus, Maaza Seyoum of the African Alliance and Peoples Vaccine Alliance Africa said. Pfizer, BioNTech and Moderna have used their monopolies to prioritise the most profitable contracts with the richest governments, leaving low-income countries out in the cold. Pfizer and BioNTech have delivered less than one percent of their total supplies to low-income countries while Moderna has delivered just 0.2 percent, the PVA said.

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction on Monday, November 15th. The shares were sold at an average price of $231.01, for a total transaction of $3,465,150.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Stephen Hoge []

Related Stocks: BX , IWD , AKTS , MRNA , AA , DKS , CLR , FTC , FRI , SPAB , SPLG , QQQ , FYT , FB , FANG ,

AstraZeneca (AZN) has revealed positive Phase IIa data from the EPICCURE trial of its injection AZD8601, which has been co-developed with Moderna (MRNA). The The post AstraZeneca, Moderna Disclose Positive Results from EPICCURE trial appeared first on Smarter Analyst .

OTTAWA - Health Canada says it has received a submission from Moderna to authorize use of its COVID-19 vaccine for children aged six to 11. The agency

Moderna is asking Health Canada to approve its COVID-19 vaccine for children aged six to 11.

(RTTNews) - Moderna, Inc. (MRNA) announced an agreement that enables the European Union and European Economic Area countries to donate doses of the Moderna COVID-19 vaccine to COVAX on an ongoing basis for delivery in 2021. The donations of Moderna vaccine to COVAX will be directed to the 92 Gavi COVAX Advance Market Commitment low- and

The Peoples Vaccine Alliance (PVA) has carried out an analysis on Pfizer, BioNTech and Moderna which suggests that the three drugmakers are making as much as $65,000 as combined profit every minute. This conclusion was based on calculations of the firms own earning reports by PVA. The profit is generated from their highly successful COVID-19 []

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement that enables the European Union (EU) and European Econ

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement that enables the European Union (EU) and European Economic Area (EEA) countries to donate doses of the Moderna COVID-19 vaccine that they have purchased under the EU Vaccines Strategy to COVAX on an ongoing basis for delivery in 2021. This initiative, led

The procedure for the administration of a booster dose for individuals aged 40 years and over starts as of tomorrow, November 17th, provided that a period of six months has elapsed since the completion of their vaccination scheme (namely the administration of a second dose in the case of Pfizer/BioNTech, Moderna and AstraZeneca vaccines or Johnson & Johnsons []